Illustration of a meditation group with mixed expressions of calm and distress, alongside a researcher, representing study on meditation side effects.
AI:n luoma kuva

Study details potential side effects of meditation practice

AI:n luoma kuva
Faktatarkistettu

New research indicates that while meditation is widely promoted for mental health, a substantial share of practitioners report unpleasant experiences, with about a third finding them distressing. Psychologist Nicholas Van Dam and colleagues say the findings underscore the need for clearer informed consent in mindfulness programs.

A study published in Clinical Psychological Science reports that meditation can produce unwanted experiences for some practitioners, including anxiety, feelings of disembodiment, and—in a minority of cases—functional impairment. The team, led by Nicholas Van Dam of the University of Melbourne, found that nearly 60% of meditators reported at least one side effect and roughly 30% described effects as challenging or distressing. About 9% reported impairment in day-to-day functioning. (sciencedaily.com)

Researchers surveyed nearly 900 adults across the United States in a cross-sectional, population-based study designed to approximate the U.S. meditator population using Centers for Disease Control and Prevention data. Participants ranged from beginners to advanced practitioners. To capture experiences systematically, the team used a 30-item checklist that asked respondents to rate intensity, whether experiences felt positive or negative, and whether they affected daily functioning. (psychologicalscience.org)

The study identified several risk factors. Individuals reporting psychological symptoms or distress in the prior 30 days were more likely to report adverse effects. Attendance at residential meditation retreats—often long and intensive—was also associated with a higher likelihood of reporting at least one effect that impaired functioning. In the sample, 58.4% reported at least one adverse effect on a standardized inventory, about 31% reported challenging or distressing experiences, and 9.1% reported functional impairment. (psychologicalscience.org)

“This is the kind of research that is done at the very beginning of developing any new treatment intervention program,” Van Dam said, noting that prior estimates of adverse effects vary widely—from about 1% in a 2018 review of randomized trials to as high as two thirds in some studies. The lower figure comes from a systematic review of mindfulness-based programs that also highlighted limited adverse-event monitoring, while higher estimates have been reported in work by Willoughby Britton and colleagues. (psychologicalscience.org)

Van Dam emphasized that the goal is awareness, not alarm. “Our conclusions are not that people should be terrified, or people should not try meditation. It’s really that we think that we should do a better job of providing informed consent,” he said, comparing the approach to how risks are disclosed before surgery or exposure therapy. He added that more longitudinal research is needed to clarify causality. “These practices are not for everyone,” he said. “If they’re not working, it might be because it’s just not a good match.” (psychologicalscience.org)

Liittyvät artikkelit

UCSF researcher Jennifer Mitchell in a lab examining MM120, an LSD-based drug for treating generalized anxiety disorder.
AI:n luoma kuva

UCSF researchers test LSD-based MM120 for generalized anxiety disorder

Raportoinut AI AI:n luoma kuva Faktatarkistettu

UCSF neuroscientist Jennifer Mitchell and collaborators are evaluating MM120, a pharmaceutical form of LSD, as a potential treatment for generalized anxiety disorder. A randomized clinical trial published in JAMA found that a single dose reduced anxiety symptoms versus placebo, with benefits persisting up to 12 weeks in the optimal dose group, according to the study and the drug’s sponsor.

A study has found that a low dose of the psychedelic 5-MeO-DMT produces brain activity patterns in an advanced Tibetan Buddhist meditator similar to those during meditation. Researchers compared the drug's effects to the lama's practiced non-dual meditation states. The findings suggest overlaps in neural responses linked to reduced self-perception.

Raportoinut AI

A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.

A comprehensive review of clinical trials indicates that tramadol, a widely prescribed opioid for chronic pain, offers only slight relief that may not be noticeable to many patients. However, it significantly increases the risk of serious side effects, particularly heart-related issues. Researchers recommend minimizing its use due to these concerns.

Raportoinut AI Faktatarkistettu

Researchers affiliated with MIT argue that transcranial focused ultrasound—a noninvasive technique that can modulate activity in deep brain regions—could enable more direct, cause-and-effect tests of how conscious experiences arise. In a “roadmap” review in *Neuroscience & Biobehavioral Reviews*, they describe experimental approaches aimed at distinguishing between competing accounts of where and how awareness is generated in the brain.

In a Jan. 2, 2026 post on Wellness Mama, founder Katie Wells argues that irritation with other people’s behavior can sometimes point to unresolved issues within ourselves. She suggests that approaching these moments with curiosity—rather than blame—can support emotional regulation, empathy and a greater sense of agency.

Raportoinut AI

In the latest assessment following prior reviews like the 2025 Annals analysis showing limited THC benefits, a Cochrane review finds cannabis-based medicines offer no clinically meaningful relief for chronic neuropathic pain versus placebo. Analyzing 21 randomized trials with over 2,100 adults, it reports no high-quality evidence of effectiveness, with only minor, insignificant improvements from THC-CBD combinations.

 

 

 

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää